Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for organ fibrosis and inflammatory diseases. Its current portfolio centers on anti-fibrotic and small-molecule drug candidates, including Hydronidone (F351) for liver fibrosis linked to metabolic dysfunction-associated steatohepatitis, as well as ETUARY (pirfenidone) for pulmonary fibrosis-related conditions. The company also advances additional programs addressing chronic liver disease and other fibrosis-driven disorders, reflecting a research and commercialization model built around targeted treatments for serious, chronic illnesses. Gyre Therapeutics, Inc. serves healthcare markets in the United States and China through its operating segments and clinical and commercial activities, positioning it as a specialized participant in the broader biotechnology sector.